Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 2Unknown 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 903Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 490Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Myelodysplastic Syndromes 244Lymphoma, Large B-Cell, Diffuse 244Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

infigratinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hypophosphatemia × Clear all
NCT03510455 2021-04-08

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 28 charts

Oncogenic osteomalacia, Hypophosphatemia

NCT00622479 2014-12-18

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Bayer

Phase 1 Terminated
12 enrolled
Genitourinary

Carcinoma, Renal Cell, Hypophosphatemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡